Week 1 of the American Association for Cancer Research (AACR) Annual Meeting was held virtually from Apr 10 - 15. Leading experts in the field presented novel and evolving insights into the biology, diagnosis and treatment of hematological malignancies.

AACR 2021

10–15 April 2021 | Virtual Meeting

First results of the 2nd H2H of iBTKs: the ALPINE study. With a 15 months follow up.
So different population from ELEVATE RR #iwCLL2021 @PeterHillmen #CLL

4

⭐@ninashah33 of @UofCalifornia gives us all the latest developments on the use of alloCAR-T therapies ⭐

Watch: 👉http://ow.ly/k1V050G7DAQ👈

@SocietyofHemOnc #SOHO2021 #HemOnc #ImmunoOnc #CART #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM

In advance of our 2nd debate at #iwCLL2021 between Peter Dreger and @drjgauthier, which type of cellular therapy do you prefer for your patients with CLL?

Very nice description of a very difficult clinical situation: Richter’s Transformation with CNS involvement. Presented by @YucaiWangMD @WeiDing3 at #iwCLL2021

Load More...

AACR 2021

10–15 April 2021 | Virtual Meeting

Week 1 of the American Association for Cancer Research (AACR) Annual Meeting was held virtually from Apr 10 - 15. Leading experts in the field presented novel and evolving insights into the biology, diagnosis and treatment of hematological malignancies.

First results of the 2nd H2H of iBTKs: the ALPINE study. With a 15 months follow up.
So different population from ELEVATE RR #iwCLL2021 @PeterHillmen #CLL

4

⭐@ninashah33 of @UofCalifornia gives us all the latest developments on the use of alloCAR-T therapies ⭐

Watch: 👉http://ow.ly/k1V050G7DAQ👈

@SocietyofHemOnc #SOHO2021 #HemOnc #ImmunoOnc #CART #BloodCancerAwarenessMonth #CancelBloodCancer #BCAM

In advance of our 2nd debate at #iwCLL2021 between Peter Dreger and @drjgauthier, which type of cellular therapy do you prefer for your patients with CLL?

Very nice description of a very difficult clinical situation: Richter’s Transformation with CNS involvement. Presented by @YucaiWangMD @WeiDing3 at #iwCLL2021

Load More...

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter